Danaher to Acquire GE Biopharma for $21.4 Billion

On February 26, Danaher announced that it had reached a final agreement with General Electric Company (GE) to acquire GE’s Biopharma business under GE Life Sciences for $21.4 billion.

As a leading supplier of instruments, consumables, and related software, GE Life Sciences is dedicated to supporting drug discovery and development in the biopharmaceutical industry, as well as the development of manufacturing processes and workflows for biologics. Its business encompasses the sales of chromatography hardware and consumables, cell culture media, and single-use products, along with R&D for instruments and consumables, and the provision of related services.

Committed to becoming a global technology innovation company, Danaher is dedicated to helping customers solve challenging and complex problems while universally improving quality of life worldwide. In the healthcare, environmental, and applied end markets, Danaher offers a portfolio of world-leading brands.

▲Danaher’s life sciences subsidiary

(Image source: Danaher official website)

GE HealthCare will join Danaher’s Life Sciences segment as an independently operated company, alongside entities such as Beckman Coulter Life Sciences and IDT.

▲Mr. Thomas P. Joyce, Jr., President and Chief Executive Officer of Danaher

(Image source: Danaher official website)

Mr. Thomas P. Joyce, Jr., President and Chief Executive Officer of Danaher, stated: “GE Healthcare Life Sciences is globally renowned for providing ‘best-in-class’ bioprocessing technologies and solutions. Beyond bringing on board a talented and passionate team, this acquisition not only adds highly innovative and industry-leading product portfolios to Danaher’s Life Sciences segment but also serves as an excellent complement to Danaher’s current solutions for biopharmaceutical manufacturing processes. In the significant and highly attractive life sciences market, Danaher anticipates that the integration of GE Healthcare Life Sciences will further drive our innovation and growth. Furthermore, this landmark acquisition enables Danaher’s commercial resources to be leveraged by GE Healthcare Life Sciences’ customers, helping them achieve breakthroughs in development and production capacity enhancement through the provision of end-to-end bioprocessing solutions.”

References:

[1]. Danaher to Acquire the Biopharma Business of General Electric Life Sciences for $21.4 Billion. Retrieved Feb. 25, 2519, from http://investors.danaher.com/2019-02-25-Danaher-to-Acquire-the-Biopharma-Business-of-General-Electric-Life-Sciences-for-21-4-Billion

(Reposted from: Sina Pharmaceutical News)

(Editor:Wang Xing）

© Copyright

Some of the public information collected on this website is sourced from the internet. The reposted content is intended solely for the purpose of disseminating information and facilitating online sharing; it does not imply that this site agrees with its viewpoints or assumes responsibility for its authenticity, nor does it constitute any other form of advice. Certain works on this site are independently submitted, published, edited, and uploaded by users. For such works, this site merely provides a platform for exchange and assumes no liability for copyright. Unless otherwise indicated, all images in the text are sourced from the internet. If you discover any content that infringes upon your intellectual property rights, please contact us, and we will promptly modify or remove it. Email: qygcbs@163.com